Artelo Biosciences Inc. (NASDAQ: ARTL) is a biopharmaceutical company dedicated to the development and commercialization of proprietary therapeutics targeting the endocannabinoid system and related biological signaling pathways. Artelo is applying true biopharma discipline toward rapidly advancing a diverse portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, pain and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the company applies leading edge scientific, regulatory and commercial discipline to develop high-impact therapies. For more information, visit the company’s website at www.artelobio.com
To view IBN’s virtual coverage of Investor Summit Group’s Q1 Virtual Summit, visit https://ibn.fm/2021InvestorSummitQ1
About InvestorBrandNetwork’s Virtual Coverage
The InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company, is providing the online investment community with a custom-built portal that includes summaries on each of the publicly traded companies participating virtually at Investor Summit Group’s Q1 Virtual Summit. In addition to enabling proficient evaluation of each company via one-click access to market research tools and helpful website links, IBN is using social media and syndicated articles to maximize the visibility of the event.
For more than a decade, IBN has provided real-time coverage for numerous global events and conferences through its various brands, social media accounts and investment newsletters. To further expand visibility of participating companies at these events, and to ensure another successful year for its event collaborations, IBN’s syndication partners have extended digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorBrandNetwork.com